Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:50 PM
Ignite Modification Date:
2025-12-24 @ 6:50 PM
NCT ID:
NCT06515457
Eligibility Criteria:
Inclusion Criteria:
* Male or female at birth, aged 40 or over
* Self-reported concerns about at least two of the following symptoms: dry eyes, red/itchy/irritated eyes, sensitivity to blue light, blurred vision (far or near)
* Generally healthy without uncontrolled chronic diseases
* Willing to avoid using new eye health prescriptions, over-the-counter medications, supplements, and herbal remedies for the study duration
* Consistent use of current eye health supplements or herbal remedies for at least 3 months prior to the study
* Willing to maintain current diet, sleep schedule, and activity level during the study
Exclusion Criteria:
* Pre-existing chronic conditions preventing protocol adherence, including oncological and psychiatric disorders
* Diagnosed diabetes (Type I or II)
* Planning to undergo any eye-related procedures during the study
* Recent surgeries or invasive treatments within the last six months
* History of major illness within the last three months
* Recent use of a supplement with active ingredients in the test product
* Severe allergic reactions requiring an EpiPen, including shellfish allergy
* Pregnant, breastfeeding, or planning to conceive
* Use of medications or herbal supplements that impact the blood
* Non-consumption of animal products for religious or personal reasons
* Unwillingness to follow the study protocol
* Anyone with a history of drug or alcohol abuse
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT06515457
Study Brief:
Protocol Section:
NCT06515457